Publications

Li, D.*, Weng, S.*, Zhong, C., et al. Risk of Second Primary Cancers Among Long-Term Survivors of Breast Cancer[J]. Frontiers in Oncology, 2020. DOI: 10.3389/fonc.2019.01426.

Cheng, Y.*, Weng, S.*, Yu, L., et al. The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors[J]. Integrative Cancer Therapies, 2019. DOI: 10.1177/1534735419876345.

Mengyuan Yang, Lizhen Zhu, Dong Xu, Shanshan Weng, et al. How should we correctly interpret biallelic germline truncating variant of MLH3 in hereditary colorectal cancer?[J]. Genetics in medicine : official journal of the American College of Medical Genetics, 2019. DOI: 10.1038/s41436-019-0529-7.

Zhu N*, Weng S*, Wang J , et al. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors[J]. Journal of Cancer Research and Clinical Oncology, 2019, 145(12).

Zhu, N., Dong, C., Weng, S., et al. A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and its Response to EGFR-TKIs[J]. Journal of the College of Physicians and Surgeons--Pakistan , 2019. DOI: 10.29271/jcpsp.2019.12.S126.

Mengyuan Yang, Xuefeng Fang, Jun Li, Dong Xu, Qian Xiao, Shaojun Yu, Hanguang Hu, Shanshan Weng, Kefeng Ding & Ying Yuan. Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing[J]. Cancer Biology & Therapy, 2019, 20(4):391-396.

Shan-Shan W, Ying C, Xiu-Jun T, et al. Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database[J]. Oncotarget, 2017, 8(15).

Chen J Q, Kong Y Y, Weng S S, et al. Outcomes of surgery for gastric cancer with distant metastases: A retrospective study from the SEER database[J]. Oncotarget, 2016, 8(3). 

Shen, H., Zhao, J., Weng, S.-S. , et al. Continuous administration of endostar plus GP chemotherapy in local advanced or metastatic lung squamous cell carcinoma[J]. Acta Medica Mediterranea, 2016, 32: 57-62. 

Pan C , Weng S , Duan Y , et al. Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer[J]. Wspó?czesna Onkologia, 2016, 4:320-326.